Evidence map›Paper›PMID 25043300›Full record

ArticleOncogene2015

DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1.

E-J Yun, S T Baek, D Xie, S-F Tseng, T Dobin, E Hernandez, J Zhou, L Zhang, J Yang, H Sun and 4 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 63 citations in OpenAlex.

  1. Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Trial
  2. Review
  3. Circular RNAs: key regulators in cancer stem cell dynamics.Molecular genetics and genomics : MGG · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

E-J YunDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
S T BaekDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
D XieDepartment of General Surgery, Tongji Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China.
S-F TsengDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
T DobinDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
E HernandezDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
J Zhou1] Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA [2] Department of Urology, The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, China.
L Zhang1] Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA [2] Department of Urology, The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, China.
J YangDepartment of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
H SunDepartment of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
G XiaoDepartment of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
D HeDepartment of Urology, The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, China.
R Kittler1] Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA [2] Eugene McDermott Center for Human Growth, University of Texas Southwestern Medical Center, Dallas, TX, USA [3] Development, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
J-T Hsieh1] Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA [2] Graduate Institute of Cancer Biology, China Medical University Hospital, Taichung, Taiwan, Republic of China.
The University of Texas Southwestern Medical Center · USXi'an Medical University · CNChina Medical University · TWFirst Affiliated Hospital of Xi'an Jiaotong University · CNTongji Hospital · CN

Funding

Developing targeted therapy with prostate cancer specific nanomedicineR01CA182670 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HSIEH, JER-TSONG, YANG, JIAN · 2013 to 2017
$1.6M
NCI NIH HHS CA182670
6 · The paper itself

Abstract

Cancer stem cell (CSC), the primary source of cancer-initiating population, is involved in cancer recurrence and drug-resistant phenotypes. This study demonstrates that the loss of DAB2IP, a novel Ras-GTPase activating protein frequently found in many cancer types, is associated with CSC properties. Mechanistically, DAB2IP is able to suppress stem cell factor receptor (c-kit or CD117) gene expression by interacting with a newly identified silencer in the c-kit gene. Moreover, DAB2IP is able to inhibit c-kit-PI3K-Akt-mTOR signaling pathway that increases c-myc protein to activate ZEB1 gene expression leading to the elevated CSC phenotypes. An inverse correlation between CD117 or ZEB1 and DAB2IP is also found in clinical specimens. Similarly, Elevated expression of ZEB1 and CD117 are found in the prostate basal cell population of DAB2IP knockout mice. Our study reveals that DAB2IP has a critical role in modulating CSC properties via CD117-mediated ZEB1 signaling pathway.

Indexed as

AnimalsCell Line, TumorGene Expression Regulation, NeoplasticGTPase-Activating ProteinsHomeodomain ProteinsHumansMaleMiceMice, KnockoutMice, SCIDNeoplasm Recurrence, LocalNeoplastic Stem CellsPhenotypePhosphatidylinositol 3-KinasesProstatic NeoplasmsProto-Oncogene Proteins c-kitDAB2IP protein, humanGTPase-Activating ProteinsHomeodomain ProteinsMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-kitProto-Oncogene Proteins c-mycras GTPase-Activating ProteinsTOR Serine-Threonine KinasesTranscription FactorsZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1

Identifiers

PMID25043300
OpenAlexW1994423181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.